Interventions of Interest
- ensifentrine (Verona Pharma)
For questions please contact Kelsey Gosselin, Program Manager, kgosselin@icer.org.
View the Key Stakeholder List.
Chronic Obstructive Pulmonary Disease
An assessment of ensifentrine
Public Meeting
June 2024
Assessment Status
Open
Upcoming Milestone
Revised Scoping DocumentView
Main Review
June 14, 2024
New England CEPAC
The Midwest CEPAC’s 2024 public meeting on ensifentrine.
Public Comment Period
See Full Timeline
11/21/2023 - 12/13/2023
Public Comments on Draft Scoping Document
Related Assessments & Policy Papers.
11/21/2023 - 12/13/2023
Public Comments on Draft Scoping Document
12/21/2023
Revised Scoping Document
01/05/2024
Research Protocol
Please find the research protocol here:
02/26/2024
Model Analysis Plan
04/10/2024 - 05/07/2024
Public Comments on Draft Evidence Report
05/30/2024
Evidence Report
06/14/2024
Evidence Presentation
07/16/2024
Public Comments
OpenView
Closed